

Mirtazapine for treatment resistant depression

Submission date 20/09/2012	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 20/09/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/12/2018	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Depression is common and most depressed patients are treated by their general practitioner (GP). Antidepressants are very widely prescribed, but a substantial proportion of those who take them do not get better. There is very little evidence to guide GPs when this happens, and most are unsure what to do when their patients do not respond to the medication. Many patients remain in a depressed state for long periods of time, despite taking antidepressant treatment. We are looking for other ways to help those whose depression does not respond to initial treatment, and we think that it might be useful to use combinations of antidepressant drugs. Combination treatments are used in many areas of medicine, including other common conditions such as hypertension and diabetes. Most of the antidepressants prescribed in the UK as first line treatment are Selective Serotonin Reuptake Inhibitors (SSRIs) like Fluoxetine (Prozac). However, there is another well-established antidepressant called Mirtazapine, that works in a different way from SSRIs and the related noradrenaline reuptake inhibitors (SNRIs). We propose a large study in general practice, where most depression is treated, to examine the effectiveness and cost-effectiveness of the combination of mirtazapine and an SSRI or SNRI.

Who can participate?

Patients from primary care who are depressed and have taken an SSRI or SNRI antidepressant for at least six weeks without substantial benefit. They must be aged between 18 and 75 and must not be suffering from a psychotic disorder or be dependent on drugs and alcohol. They must not be pregnant.

What does the study involve?

Participants who agree will be randomly allocated to receive either mirtazapine treatment or a dummy drug (placebo) that appears identical. Neither the participant, GP, or study investigator will know whether the participant is taking mirtazapine or placebo. They will continue to take their SSRI antidepressant and be treated by their GP in the usual way.

What are the possible benefits and risks of participating?

If it proves effective, this combination has the potential to rapidly make a difference for people with depression that does not respond to usual first line antidepressant treatment. Mirtazapine has been licensed in the UK for the treatment of depression since 1994, and its adverse effect

profile is well known. Its principal effects are increase in appetite, weight gain and drowsiness. Mirtazapine continues to be used in psychiatric settings in combination with other antidepressants without the reporting to date of any unexpected or new adverse events.

Where is the study run from?

Bristol University. The other participating centres are the Universities of Exeter, Manchester and York.

When is study starting and how long is it expected to run for?

The study begins in January 2013 and will run for 42 months

Who is funding the study?

NIHR Health Technology Assessment Programme (HTA)

Who is the main contact?

Dr David Kessler

david.kessler@bristol.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr David Kessler

ORCID ID

<http://orcid.org/0000-0001-5333-132X>

Contact details

University of Bristol

School of Social & Community Medicine

Oakfield House

Oakfield Grove

Bristol

United Kingdom

BS8 2BN

-

david.kessler@bristol.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

HTA 11/129/76

Study information

Scientific Title

A double blind placebo-controlled randomised trial of the addition of mirtazapine for patients with depression in primary care who have not responded to at least 6 weeks of treatment with a selective serotonin reuptake inhibitor or serotonin and noradrenaline reuptake inhibitor.

Acronym

MIR

Study objectives

That the addition of mirtazapine will improve outcome in depressed patients from primary care who have not responded to an SSRI antidepressant after at least 6 weeks of treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East Wales Research Ethics Committee C, 25/01/2013, ref: 12/WA/0353

Study design

A two parallel group multi-centre pragmatic placebo-controlled randomised trial with allocation at the level of the individual

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Depression

Interventions

The addition of Mirtazapine to SSRI antidepressants

Added 27/07/2017:

To investigate whether combining mirtazapine with Serotonin-Noradrenaline Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants results in better patient outcomes and more efficient NHS care than SNRI or SSRI therapy alone in Treatment Resistant

Depression (TRD).

Design: MIR is a two-parallel group, multi-centre, pragmatic, placebo controlled, randomised trial with allocation at the level of the individual.

Interventions: Participants are randomised to receive either oral mirtazapine or matched placebo, starting at 15mg daily for two weeks and increasing to 30mg daily thereafter, for up to 12 months to be taken in addition to their usual antidepressant.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Mirtazapine

Primary outcome measure

Change in Beck Depression Inventory score at 12 weeks (added 27/07/2017: measured using the BDI-II) measured as a continuous variable

Secondary outcome measures

Current secondary outcome measures:

The following are measured at 12, 24, and 52 weeks:

1. Response
2. Remission of depression symptoms
3. Changes in anxiety symptoms
4. Adverse Effects
5. Quality of life
6. Adherence to antidepressant medication
7. Health and social care use
8. Time off work
9. Cost effectiveness

All outcomes are analysed on an intention to treat basis.

Previous secondary outcome measures:

1. 50% improvement in BDI score (remission)
2. A measure of anxiety (GAD7)
3. Quality of life (EQ-5D-5L)
4. Health care utilisation

Overall study start date

01/01/2013

Completion date

30/06/2016

Eligibility

Key inclusion criteria

1. Aged 18-75 years
2. Currently taking any of the following SSRI or SNRI antidepressants, for at least 6 weeks at recommended (BNF) doses:
 - 2.1. Fluoxetine
 - 2.2. Sertraline
 - 2.3. Citalopram
 - 2.4. Escitalopram
 - 2.5. Fluvoxamine
 - 2.6. Paroxetine
 - 2.7. Duloxetine
 - 2.8. Venlafaxine and who have done so for at least 6 weeks at
3. Patients who score 14 or more on the Beck Depression Inventory (BDI)
4. Patients who have adhered to their medication and meet ICD-10 criteria for depression (assessed using the Computerised Interview Schedule Revised version (CIS-R))

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

75 Years

Sex

Both

Target number of participants

400

Key exclusion criteria

GPs will be asked to exclude patients who have bipolar disorder, psychosis or alcohol/substance abuse/dependence or who are pregnant. In addition, we will exclude patients who: are not able to complete the study questionnaires or have a past history of an adverse reaction to mirtazapine.

Date of first enrolment

01/01/2013

Date of final enrolment

30/06/2016

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

University of Bristol

Bristol

United Kingdom

BS8 2BN

Study participating centre

University Of Exeter Medical School

St Lukes Campus

Magdalen Road

Exeter

United Kingdom

EX1 2LU

Study participating centre

Keele University

Primary Care And Health Sciences

Keele

United Kingdom

ST5 5BG

Study participating centre

Hull York Medical School

Cottingham Road

Hull

United Kingdom

HU6 7RX

Sponsor information

Organisation

University of Bristol (UK)

Sponsor details

c/o Dr Birgit Whitman

Research Governance and Compliance Manager

Research and Enterprise Development

Senate House

Tyndall Avenue
Bristol
England
United Kingdom
BS8 1TH

-

Birgit.Whitman@bristol.ac.uk

Sponsor type

University/education

Website

<http://www.bris.ac.uk/>

ROR

<https://ror.org/0524sp257>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal.

Intention to publish date

Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	03/02/2016		Yes	No
Results article	results	31/10/2018		Yes	No
Results article	results	01/11/2018		Yes	No
Results article	qualitative study results	14/12/2018		Yes	No
HRA research summary			28/06/2023	No	No